About ▼ Careers Internship MedBlog Contact us

MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy

- Company plans to announce interim safety and RECIST data Q1 2018 -

Latest Press Release on Clinical Trials News

Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib

SHANGHAI , April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time) , Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment f...

Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease

Dosing of first patient completed in Cohort 2 following Data Monitoring Committee approval to proceed Encouraging safety, tolerability and early pharmacodynamic changes observed i...

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; The response rate increased by 89.4% compared to...

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

SHENZHEN, China , March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: ...

myTomorrows Partners with The ALS Association to Support ALS Patients in Accessing Clinical Trials

Partnership with leading US-based ALS patient advocacy group furthers myTomorrows' mission of ensuring that patients confronting life-threatening diseases are aware of all possible trea...

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use Ok, Got it. Close